Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was up 6.1% during mid-day trading on Monday . The stock traded as high as $12.90 and last traded at $12.75. Approximately 322,163 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 1,190,832 shares. The stock had previously closed at $12.02.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC restated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $35.70.
View Our Latest Research Report on VRDN
Viridian Therapeutics Stock Performance
The business has a 50 day moving average price of $14.55 and a two-hundred day moving average price of $18.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market cap of $1.07 billion, a P/E ratio of -3.05 and a beta of 0.81.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.
Institutional Trading of Viridian Therapeutics
Institutional investors have recently modified their holdings of the company. Lord Abbett & CO. LLC bought a new position in Viridian Therapeutics in the third quarter worth about $8,917,000. JPMorgan Chase & Co. increased its position in shares of Viridian Therapeutics by 218.5% during the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock valued at $9,108,000 after acquiring an additional 274,641 shares in the last quarter. Barclays PLC lifted its position in Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company's stock valued at $2,851,000 after acquiring an additional 66,550 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Viridian Therapeutics by 1,603.4% in the 3rd quarter. Principal Financial Group Inc. now owns 172,810 shares of the company's stock worth $3,931,000 after purchasing an additional 162,665 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after purchasing an additional 14,644 shares during the last quarter.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
